5 Best Peptides for Peripheral Artery Disease

What to Know Before Choosing a Peptide for Peripheral Artery Disease

Peripheral artery disease is caused by atherosclerosis, the progressive narrowing of arteries by fatty deposits, which restricts blood flow primarily to the legs and feet. The honest starting point for this guide is that no peptide has been specifically approved to treat PAD. What does exist is a small, genuinely interesting field of compounds that people use or are actively discussing for their relevance to the condition's core mechanisms: inflammation, endothelial dysfunction, and a relative deficit in angiogenesis, meaning the body's capacity to grow new blood vessels and route around damaged ones.

Every compound in this list earned its slot under one criterion: people use it, or are actively discussing using it, for this goal. That criterion is deliberately broad. FDA-approved compounds qualify. So do telemedicine-prescribed ones, research-only compounds, and compounds whose evidence comes primarily from preclinical models or a specialized research program with limited Western peer-reviewed validation. Evidence strength for each is described honestly inside each entry, and you will find a wide range here. The numbers in front of each entry are a spine for the list, not a ranking. The order reflects how prominently each compound appears in published research and real-world use for PAD, not a recommendation of one compound over another. The right choice for any individual depends on their health history, current medications, and a conversation with their physician.

1. Semaglutide: The Only Peptide With a PAD-Specific Randomized Trial

Semaglutide is a GLP-1 receptor agonist, a class of peptide medications that activate receptors in the gut, pancreas, and vascular system. It is FDA-approved for type 2 diabetes under the brand name Ozempic and for obesity under Wegovy, and it is available through telemedicine platforms in the United States for those indications. In June 2025, the European Medicines Agency became the first regulatory body to formally endorse adding PAD-related walking benefits to semaglutide's label in Europe. The FDA is reviewing a comparable label update as of 2026.

The evidence for semaglutide in PAD is the strongest of any peptide on this list. The STRIDE trial, published in The Lancet in 2025, randomized PAD patients with type 2 diabetes to weekly semaglutide injections versus placebo. Those receiving semaglutide showed a 13 percent improvement in mean walking distance and an 11 percent improvement in pain-free walking compared to the placebo group. A large retrospective study covering more than 100,000 patients found that those on GLP-1 medications had a major adverse limb event rate of roughly 0.8 percent at one year, compared to 1.5 percent in non-users, a relative reduction of nearly half. A study published in the Journal of the American Heart Association found lower amputation risk with liraglutide, a related GLP-1 receptor agonist, compared to sulfonylureas in patients with diabetes and PAD. The ACC and AHA recognized GLP-1s as beneficial for PAD patients with type 2 diabetes in their 2026 clinical guidelines.

The mechanisms connect directly to what drives PAD. Semaglutide reduces systemic inflammation, which is one of the primary forces pushing atherosclerotic plaque forward. It improves endothelial function, the health of the inner lining of blood vessels that governs blood flow and vascular resistance. It also lowers blood glucose, visceral fat, and oxidative stress, all of which contribute to the metabolic environment that accelerates arterial damage. Being precise about the practical picture matters here: semaglutide is not prescribed for PAD in isolation. Patients who have PAD alongside type 2 diabetes or obesity can be prescribed it for those approved indications, and the PAD vascular benefits are increasingly part of that prescribing conversation. Common side effects include nausea, vomiting, and gastrointestinal symptoms, most pronounced early in treatment. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 cannot use it.

2. Tirzepatide: The Dual-Receptor GLP-1 With Emerging Vascular Data

Tirzepatide activates two receptors simultaneously: the GLP-1 receptor and the GIP receptor, where GIP stands for glucose-dependent insulinotropic polypeptide, a second incretin hormone involved in metabolic signaling. FDA-approved for type 2 diabetes under the name Mounjaro and for obesity under Zepbound, it is available through telemedicine for those indications and has shown stronger effects on weight loss and metabolic markers than semaglutide in head-to-head comparisons.

Its relevance to PAD runs along the same mechanistic pathways as semaglutide: reduced inflammation, improved endothelial function, lower oxidative stress, and better metabolic control of the drivers that fuel atherosclerotic progression. The large retrospective study of more than 100,000 patients did include tirzepatide users, who made up roughly 12 percent of the GLP-1 cohort, and that cohort as a whole showed the favorable limb outcome data noted above. No dedicated PAD randomized controlled trial for tirzepatide exists the way the STRIDE study does for semaglutide. Its vascular benefits are inferred from the broader GLP-1 evidence base, its stronger metabolic potency, and the mechanistic overlap between the two compounds.

For patients with PAD and diabetes or obesity who are candidates for a GLP-1, tirzepatide's availability and metabolic strength make it part of the clinical conversation about vascular risk reduction. The safety profile closely mirrors semaglutide, with nausea and gastrointestinal effects as the most common concerns, and the same thyroid-related contraindications apply.

3. BPC-157: For Its Angiogenic Mechanism

BPC-157 is a synthetic peptide derived from a protective protein found in gastric juice, and it is one of the most widely discussed compounds in biohacking and research-chemical communities for tissue repair, tendon healing, and gut recovery. It is not FDA-approved for any indication and is sold as a research chemical.

Its connection to PAD is mechanistic rather than clinical. The core problem in PAD is a relative deficit in angiogenesis, the body's capacity to grow new blood vessels that can route around narrowed or blocked arteries. BPC-157 has been studied in animal models for its ability to upregulate VEGF, which stands for vascular endothelial growth factor, the molecular signal that tells the body to build new blood vessels. This is the same pathway that experimental angiogenic therapies for PAD are trying to activate. BPC-157 also shows anti-inflammatory effects in preclinical work and has been studied for its influence on nitric oxide pathways, which play a role in vasodilation and arterial tone.

No human clinical trial has tested BPC-157 in PAD patients as of 2026. The available evidence is entirely preclinical, from rodent models and in vitro studies. No community reports of people using BPC-157 specifically for PAD with reported outcomes were found in the research for this guide. Its presence in PAD discussions comes from the mechanistic overlap between what it does in animal models and what PAD's biology requires. That overlap is real, and it is worth naming. The evidence here is animal-derived and mechanistic, not human-clinical, and no established PAD-specific protocol exists. No serious adverse effects have been documented in general human use reports, though long-term safety data does not exist and regulatory oversight does not apply to research chemicals. People managing a serious vascular condition should not treat a research chemical as a substitute for physician-supervised care.

4. Vesugen: The Khavinson Vascular Bioregulator

Vesugen is a tripeptide made of three amino acids, specifically lysine, glutamic acid, and aspartic acid. It was developed within the Khavinson peptide bioregulator system, a research program originating at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Khavinson peptides are short amino acid sequences proposed to act as gene expression regulators, the theory being that they interact with chromatin to upregulate tissue-specific gene expression inside the cell nucleus. Vesugen is positioned within that system as a vascular bioregulator, meaning its proposed target tissue is blood vessel walls.

The direct relevance to PAD comes from its proposed mechanism: supporting endothelial cell function and vascular smooth muscle cell health, both of which are compromised as PAD progresses. A compound that maintains those cell populations could theoretically slow arterial wall degradation or support the development of collateral circulation that compensates for blocked flow.

No clinical trial data exists specifically for Vesugen in PAD as of 2026. The broader Khavinson research program has produced published work in Russian-language journals on peptide bioregulators and aging, but this body of research has limited Western peer-reviewed validation and no randomized controlled trial data for PAD specifically. No community reports of Vesugen use specifically for PAD with reported outcomes were found. Its appearance in PAD discussions is driven by its marketed purpose as a vascular bioregulator and its alignment with the biological targets relevant to the condition, not by clinical outcome data. Vesugen is typically available in oral capsule form through specialty European supplement suppliers. Oral bioavailability is a real question for short peptides, which are susceptible to degradation in the gastrointestinal tract before reaching systemic circulation. No serious adverse effects have been documented, it is not FDA-approved, and it falls outside any established PAD treatment pathway.

5. Ventfort: Dipeptide Companion in the Khavinson Vascular System

Ventfort is a dipeptide made of two amino acids, lysine and glutamic acid, from the same Khavinson bioregulator system as Vesugen. Where Vesugen is the tripeptide targeting vascular tissue in that classification, Ventfort is the corresponding dipeptide, often described as the vascular system peptide in Khavinson protocols. The two are frequently used together in programs addressing cardiovascular aging, and their proposed mechanisms are closely related.

The rationale for Ventfort in PAD follows the same logic as Vesugen: short peptide sequences that interact with vascular tissue at the gene expression level to support endothelial cell and vascular smooth muscle cell function, potentially maintaining arterial wall integrity and supporting the development of collateral vessels.

No human clinical trial data has been published for Ventfort in PAD as of 2026. Its evidence base is the same as Vesugen's, drawing from the Khavinson bioregulator research program with the same limitations in Western peer-reviewed validation. No community reports of Ventfort use for PAD with reported outcomes were found. Its place in PAD conversations is conceptual, based on its marketed vascular targeting and its structural relationship to Vesugen. The availability, format, and safety profile are essentially the same as Vesugen: oral capsule delivery with the same bioavailability questions, no documented serious adverse effects, no FDA approval, and no role in any established PAD clinical pathway. People who use Khavinson bioregulators for general cardiovascular aging protocols often include both Ventfort and Vesugen together, and that is the context in which PAD relevance is most often raised.

How These Peptides Compare

Frequently Asked Questions

Are any peptides actually approved to treat PAD?

As of 2026, no peptide has been specifically approved to treat PAD in the United States, though the European Medicines Agency endorsed adding PAD walking benefits to semaglutide's label in 2025. The GLP-1 class is available by prescription for type 2 diabetes and obesity, and physicians increasingly factor in PAD vascular benefits when prescribing for those indications. BPC-157, Vesugen, and Ventfort are not approved for any indication and are not part of any recognized clinical treatment pathway for PAD.

What makes GLP-1s relevant to PAD if they are diabetes medications?

GLP-1 receptor agonists were developed for metabolic conditions, but their vascular effects are real and operate independently of blood sugar control. They reduce systemic inflammation, improve the health of the arterial lining, and address the oxidative stress that drives atherosclerotic progression. PAD is fundamentally a disease of damaged arteries in a hostile metabolic environment, and GLP-1s address that environment directly. The STRIDE trial demonstrated this with measurable walking distance improvements in PAD patients, which is why regulatory bodies are beginning to recognize PAD as a relevant benefit of these medications.

Why are BPC-157, Vesugen, and Ventfort on this list without PAD clinical data?

They belong because the inclusion criterion for this guide is whether people use or discuss a compound for a goal, not whether it has cleared a clinical trial for that specific indication. BPC-157 is discussed for PAD because its preclinical angiogenesis mechanism directly addresses one of PAD's core deficits. Vesugen and Ventfort appear because they are marketed as vascular bioregulators and appear in discussions about vascular aging and PAD. Being honest about their evidence is more useful than quietly omitting them. The clear statement here is that none of them have human trial data for PAD, and that distinction matters when weighing options.

Is it safe to manage PAD with peptides without a doctor?

No. PAD is a serious vascular condition that carries real risks of limb loss and cardiovascular events, and managing it requires physician supervision regardless of which compounds or medications are involved. The GLP-1s on this list are prescription medications with real contraindications and drug interaction considerations. The research-chemical compounds have no regulatory oversight and no PAD-specific safety data at all. A guide can map the field of compounds people discuss, but it cannot substitute for professional medical management of a condition at this level of seriousness.

How does the angiogenesis deficit in PAD connect to the peptides on this list?

PAD creates a situation where arterial damage outpaces the body's ability to compensate by growing new blood vessels around blockages. That growth process is angiogenesis, and it is the shared biological thread connecting several compounds here. BPC-157 upregulates VEGF, the key signal for new blood vessel formation, in animal models. Vesugen and Ventfort are proposed to support the vascular cell populations that participate in that same process. GLP-1s address the inflammatory and metabolic environment that suppresses angiogenic capacity. Those connections have not been confirmed in PAD patients through clinical trials, with the exception of the GLP-1 outcome data, but the mechanistic thread is coherent and worth understanding.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for peripheral artery disease in one place.